These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27067142)

  • 1. Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.
    Mancinelli S; Galluzzo CM; Andreotti M; Liotta G; Jere H; Sagno JB; Amici R; Pirillo MF; Scarcella P; Marazzi MC; Vella S; Palombi L; Giuliano M
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):737-42. PubMed ID: 27067142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.
    Galluzzo C; Liotta G; Andreotti M; Luhanga R; Jere H; Mancinelli S; Maulidi M; Sagno JB; Pirillo M; Erba F; Amici R; Ceffa S; Marazzi MC; Vella S; Palombi L; Giuliano M
    J Med Virol; 2012 Oct; 84(10):1553-7. PubMed ID: 22930502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.
    Palombi L; Galluzzo CM; Andreotti M; Liotta G; Jere H; Sagno JB; Luhanga R; Mancinelli S; Amici R; Marazzi MC; Vella S; Giuliano M
    J Antimicrob Chemother; 2015 Oct; 70(10):2881-4. PubMed ID: 26111981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
    J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi.
    Palombi L; Galluzzo CM; Pirillo MF; Liotta G; Andreotti M; Jere H; Sagno JB; Luhanga R; Mancinelli S; Ceffa S; Amici R; Marazzi MC; Vella S; Giuliano M
    J Antimicrob Chemother; 2014 Mar; 69(3):749-52. PubMed ID: 24135952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
    Kakehasi FM; Tupinambás U; Cleto S; Aleixo A; Lin E; Melo VH; Aguiar RA; Pinto JA
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1515-20. PubMed ID: 18160009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.
    Wallis CL; Papathanasopolous MA; Fox M; Conradie F; Ive P; Orrell C; Zeinecker J; Sanne I; Wood R; McIntyre J; Stevens W;
    Antivir Ther; 2012; 17(2):313-20. PubMed ID: 22293461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.
    Manosuthi W; Tantanathip P; Prasithisirikul W; Likanonsakul S; Sungkanuparph S
    BMC Infect Dis; 2008 Oct; 8():136. PubMed ID: 18851761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
    De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
    BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
    Lyons FE; Coughlan S; Byrne CM; Hopkins SM; Hall WW; Mulcahy FM
    AIDS; 2005 Jan; 19(1):63-7. PubMed ID: 15627034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania.
    Ngarina M; Kilewo C; Karlsson K; Aboud S; Karlsson A; Marrone G; Leyna G; Ekström AM; Biberfeld G
    BMC Infect Dis; 2015 Apr; 15():175. PubMed ID: 25886277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
    Paredes R; Cheng I; Kuritzkes DR; Tuomala RE;
    AIDS; 2010 Jan; 24(1):45-53. PubMed ID: 19915448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT.
    Machnowska P; Hauser A; Meixenberger K; Altmann B; Bannert N; Rempis E; Schnack A; Decker S; Braun V; Busingye P; Rubaihayo J; Harms G; Theuring S
    PLoS One; 2017; 12(5):e0178297. PubMed ID: 28562612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis.
    Duran AS; Losso MH; Salomón H; Harris DR; Pampuro S; Soto-Ramirez LE; Duarte G; de Souza RS; Read JS;
    AIDS; 2007 Jan; 21(2):199-205. PubMed ID: 17197811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
    Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.